Tenofovir treatment in patients with lamivudine-resistant hepatitis B mutants strongly affects viral replication [1]

Hepatology

Volumn 36, Issue 2, 2002, Pages 507-508

  Van Bömmel, Florian ^a   Wünsche, Thomas ^a   Schormann, Dirk ^a   Berg, Thomas ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

LAMIVUDINE; TENOFOVIR; TENOFOVIR DISOPROXIL;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL ARTICLE; DRUG EFFICACY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LETTER; MALE; PRIORITY JOURNAL; VIRUS INHIBITION; VIRUS MUTATION; VIRUS REPLICATION;

ADENINE; DRUG RESISTANCE, VIRAL; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; LAMIVUDINE; MUTATION; ORGANOPHOSPHORUS COMPOUNDS; PHOSPHONIC ACIDS; REVERSE TRANSCRIPTASE INHIBITORS; VIRUS REPLICATION;

EID: 0036324405     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.2002.35328     Document Type: Letter

References (8)

1. Management of hepatitis B 2000-Summary of a workshop
2. Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region
3. Adefovir Dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants
4. Tenofovir approved: Broad indication
5. Tenofovir exhibits low cytotoxicity in various human cell types: Comparison with other nucleoside reverse transcriptase inhibitors
6. New drug for HIV-1 infection. From the Food and Drug Administration
7. Phase I/II trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults
8. Inhibition of the replication of the DNA polymerase M550V mutation variant of human hepatitis B virus by adefovir, tenofovir, L-FMAU, DADP, penciclovir and lobucavir